Earlier this week, Rhythm Pharmaceuticals was in the news for arranging a new financing package tied to its rare-obesity drug business. On Wednesday, November 4, it was in the news because AstraZeneca reportedly wanted to buy the whole company.
The Wall Street Journal reported that AstraZeneca had made a $124-per-share offer for Rhythm the previous month. Reuters, citing three people familiar with the matter, reported a non-binding proposal worth approximately $10 billion, reaching as high as $134 per share including milestone-related payments.
Rhythm Pharmaceuticals shares jumped 28% on November 4, closing at $110.68. By Friday, November 6, they had closed at $112.28. Neither company had publicly confirmed a binding acquisition agreement in the reporting reviewed.
That price is striking for a company that generated $92.1 million in quarterly product sales. It also challenges the assumption that every multibillion-dollar obesity acquisition is really a bet on the next GLP-1 blockbuster.
Rhythm sells Imcivree, the brand name for setmelanotide, a peptide drug targeting the melanocortin-4 receptor, or MC4R. Its patients are not the broad population using Wegovy or Zepbound. They have rare conditions in which the brain’s appetite-regulation system is impaired.
That distinction is central to the reported AstraZeneca interest. The attraction appears to be an approved specialist medicine, a rapidly expanding rare-obesity franchise and a pipeline built around the same biological pathway.
What Was Actually Reported About AstraZeneca’s Rhythm Bid
The acquisition story rests on reporting by two major news organizations, not a company announcement.
On November 4, The Wall Street Journal reported that AstraZeneca had offered $124 per share for Rhythm in October.
Reuters subsequently reported that the proposal could reach $134 per share, including payments linked to unspecified milestones, and valued the potential transaction at approximately $10 billion.
Reuters also reported that AstraZeneca would pursue the acquisition through Alexion, the rare-disease business it bought for $39 billion in 2021.
The companies had not confirmed the proposed terms. AstraZeneca declined to comment, while Rhythm did not provide confirmation of an agreed transaction.
The reported price structure requires particular care.
A $124-per-share proposal is not necessarily equivalent to $134 in guaranteed cash. The higher figure was reported to include milestone-related payments, and the public accounts do not establish the conditions, timing or certainty of that additional consideration.
Before the takeover report, Rhythm shares closed at $86.44 on November 3. The earlier $124 figure would represent a premium of approximately 43% to that price.
On November 4, shares closed at $110.68, giving Rhythm a market capitalization of approximately $7.64 billion. They fell to $105.02 the following day before recovering to $112.28 on November 6.
The market was clearly assigning some value to the takeover possibility while still trading below the reported proposal.
That difference is not guaranteed shareholder upside. A non-binding proposal can change, be rejected or fail to produce a transaction.
A reported offer shows interest. It does not establish that a buyer and seller have agreed on a price.
Why Imcivree Is Different From the GLP-1 Obesity Market
Imcivree is a melanocortin-4 receptor agonist, a peptide designed to activate a central pathway involved in hunger, appetite regulation and energy balance.
That mechanism is distinct from the GLP-1 receptor targeted by semaglutide and from the combined GLP-1 and GIP pathways activated by tirzepatide.
It also places Imcivree in a different commercial category.
Setmelanotide was first approved by the FDA in 2020 for certain rare inherited obesity conditions. Its authorized uses subsequently expanded to include Bardet-Biedl syndrome and other specific indications.
The turning point for Rhythm’s 2026 commercial story came on March 19, when the FDA expanded Imcivree’s indication to acquired hypothalamic obesity in adults and children aged four years and older.
Acquired hypothalamic obesity occurs when injury or dysfunction of the hypothalamus disrupts the biological systems that regulate hunger and weight.
The condition may follow a brain tumor, its treatment or other forms of hypothalamic injury. Patients can experience severe and sustained weight gain that does not respond adequately to conventional approaches.
Imcivree became the first FDA-approved therapy specifically for acquired hypothalamic obesity.
The approval was supported by the Phase 3 TRANSCEND study involving 142 patients. At 52 weeks, the setmelanotide group recorded a mean BMI reduction of 15.8%, while the placebo group recorded a 2.6% increase, producing an 18.4-percentage-point placebo-adjusted difference.
Those findings provided clinical evidence for the expanded indication, although the BMI result should not be confused with an identical percentage change in body weight.
The medicine is not approved for general obesity unrelated to its specified indications. It also has an established safety profile requiring clinical monitoring, including for pigmentation changes, gastrointestinal symptoms and other warnings in its prescribing information.
That combination of a defined patient population, regulatory approval and specialized treatment creates a different commercial proposition from selling weight-loss prescriptions to millions of people.
The GLP-1 market is built around scale. Rhythm’s attraction is a narrower population with a specific biological problem and an approved treatment.
The $92 Million Quarter That Changed the Valuation Story
Rhythm’s November 3 earnings announcement provides the clearest evidence of the commercial opportunity.
The company reported $92.1 million in global net product revenue from Imcivree during the third quarter of 2026, compared with $51.3 million in the same quarter a year earlier.
Revenue increased 29% compared with the preceding quarter, driven by commercial momentum in the United States and continued international growth.
The company also reported receiving more than 700 patient start forms for acquired hypothalamic obesity from more than 500 prescribers in the United States by September 30.
That figure signals prescribing interest. It is not a count of 700 patients already receiving and continuing treatment.
Each form still has to move through the practical processes of coverage determination, treatment initiation and ongoing access.
For a specialized rare-disease medicine, that conversion process matters. A buyer valuing future sales must estimate how many eligible patients can be diagnosed, referred, reimbursed and retained on treatment.
The company also reported nine-month net product revenue of $223.5 million through September 30, reinforcing the growing size of its commercial franchise.
But the reported takeover valuation implies far more than the revenue already on the books.
A buyer paying close to $10 billion would be assuming meaningful future growth from the hypothalamic obesity launch, international expansion and potentially additional indications or pipeline treatments.
The question is not whether Imcivree is selling. The latest results show that it is.
The question is how much larger this narrowly defined market can become, and how much of that opportunity is already reflected in Rhythm’s share price.
Why Alexion Makes Sense, and Why the Financing Matters
The reported involvement of Alexion is an important detail.
AstraZeneca acquired Alexion in 2021 to expand its position in rare diseases, adding specialist products and commercial infrastructure distinct from its broader pharmaceutical businesses.
Rare-disease medicines commonly require specialized diagnostic pathways, relatively small groups of prescribing physicians and complicated reimbursement arrangements.
Those characteristics are closer to Alexion’s established business model than to the mass-market competition surrounding weekly GLP-1 obesity injections.
Analysts quoted in post-report coverage described Rhythm as a strategic fit for AstraZeneca’s rare-disease presence, although no public company statement has confirmed that as the rationale for a proposed acquisition.
There is also a financial wrinkle.
On November 2, Rhythm announced a five-year term-loan facility offering access to up to $750 million, led by KKR’s HealthCare Royalty in partnership with Blackstone.
Of that total, $500 million was committed, including an initial $250 million draw at closing. The remaining potential availability was subject to the terms of the facility.
Rhythm also amended its license agreement with LG Chem for bivamelagon and its broader MC4R drug portfolio, agreeing to $350 million in additional fixed payments over several years in exchange for changes to its royalty obligations.
We examined the financing announcement in our earlier report on Rhythm’s loan and royalty agreement.
These arrangements were designed to provide financial flexibility while the company expanded commercialization and funded additional drug development.
They also show why a potential buyer would need to examine more than reported product revenue. Rhythm’s valuation involves existing financing obligations, licensing payments, future royalties and the economics of an expanding research portfolio.
That does not make a takeover less plausible. It makes the underlying valuation more complicated than multiplying one quarter’s sales by a large number.
The Pipeline Is Another Part of the Possible $10 Billion Prize
Imcivree is the marketed product, but it is not the full Rhythm story.
Rhythm is developing additional therapies aimed at the MC4R pathway, including bivamelagon, an investigational oral MC4R agonist originally developed by LG Chem.
In its November 3 business update, Rhythm said it planned to advance bivamelagon into pivotal development for acquired hypothalamic obesity and Prader-Willi syndrome.
Prader-Willi syndrome is a complex genetic condition that can involve severe hyperphagia, or persistent, difficult-to-control hunger.
An oral MC4R medicine with convincing efficacy and safety could potentially serve patients who would prefer an alternative to a daily injection, although pivotal evidence and regulatory approval would still be required.
Rhythm has also described additional work on RM-718 and other programs targeting rare neuroendocrine conditions.
That matters when interpreting the price.
Analysts at Jefferies, Leerink Partners and William Blair suggested after the takeover report that the company could attract further interest, with particular attention to its rare-obesity franchise and pipeline.
On November 6, speculative market reports also circulated about a possible additional bidder. Those reports did not establish the identity of a confirmed competing acquirer or a binding alternative offer.
A bidding war remains a possibility discussed by the market, not a verified fact.
Meanwhile, the wider obesity sector continues to pursue a different approach: acquiring or licensing experimental drugs with the hope of reaching much larger patient populations.
We covered one example in our report on Novo Nordisk’s potential $2.6 billion Chinese obesity-drug partnership.
Rhythm represents a contrasting strategy. It already has an approved medicine generating revenue, together with a development pipeline concentrated on a specialized biological pathway.
The opportunity may be smaller in patient numbers, but it is further along commercially than many experimental obesity assets.
What to Watch Before Calling This a Deal
The most important unanswered question is whether AstraZeneca and Rhythm will reach an agreement at all.
A reported non-binding proposal does not require Rhythm to accept the price, and it does not obligate AstraZeneca to complete a purchase.
The specific milestone payments included in the reported $134 maximum also remain unclear.
Investors should therefore distinguish between an established transaction and a share price being influenced by takeover reporting.
A confirmed company announcement, a binding acquisition agreement, revised offer terms, regulatory disclosures or a formally identified competing bidder would materially change the story.
Until then, the proposed price and ultimate outcome remain uncertain.
For patients with acquired hypothalamic obesity, the consequences of any ownership change would be more practical than financial.
Continued access to Imcivree, reliable drug supply, insurance coverage and availability of clinicians familiar with the condition would matter more than the headline acquisition price.
For the industry, the reported approach offers a useful correction to the standard obesity-drug narrative.
Much of the market is competing to produce more weight loss for millions of people, using GLP-1-based drugs, oral treatments and combination medicines.
Rhythm is pursuing something different: treatment of particular rare disorders in which disrupted appetite signaling creates severe unmet medical need.
The commercial value of that approach now appears large enough to attract reported interest from one of the world’s largest pharmaceutical companies.
The biggest obesity markets are measured in millions of patients. One of the most interesting reported acquisition targets serves a fraction of that population.
Sources
Takeover reporting: Reuters — AstraZeneca Made $10 Billion Offer for Obesity Drugmaker Rhythm, Sources Say. November 4, 2026.
Original reported offer: The Wall Street Journal — AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals. November 4, 2026.
Company financial results: Rhythm Pharmaceuticals — Third Quarter 2026 Financial Results and Business Update. November 3, 2026.
FDA approval: Rhythm Pharmaceuticals — FDA Approval of Imcivree for Acquired Hypothalamic Obesity. March 19, 2026.
Official prescribing information: DailyMed / FDA — Imcivree (setmelanotide) Full Prescribing Information. Updated 2026.
Financing and pipeline: Rhythm Pharmaceuticals — LG Chem Bivamelagon License Amendment and Term Loan Facility. November 2, 2026.
Analyst reaction: Fierce Pharma — AstraZeneca Said to Offer $10B to Acquire Rhythm; Analysts Discuss Potential Bidding War. November 5, 2026.
Market data: Stock Analysis — Rhythm Pharmaceuticals Historical Share Prices. Closing prices through November 6, 2026.
Unconfirmed additional-bidder speculation: Seeking Alpha — Rhythm Pharmaceuticals Gains on Report of Additional Bidder. November 6, 2026.
